Sort
4,870 grants matching “glp 1”
National Center for Canine Models Muscular Dystrophy (NCDMD)
$991,633Joe N Kornegay · Univ Of North Carolina Chapel Hill · U24 · FY2008 · NS
Cyclic Orynotides for Systemic MDR Candidiasis
$991,551Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2021 · AI
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
$991,186Thomas Edward Smithgall · Fox Chase Chemical Diversity Center, Inc · R42 · FY2017 · GM
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
$991,117Terry Roemer · Prokaryotics, Inc. · R44 · FY2023 · AI
BCG overexpressing a small molecule STING agonist as a vaccine for TB
$991,112Todd Wallach · Oncosting Llc · R44 · FY2025 · AI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases
$990,946Jay L Rothstein · Immunext, Inc. · R44 · FY2021 · AI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents
$990,305Terry L Bowlin · Microbiotix, Inc · R44 · FY2013 · AI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
$990,104Neil A Fanger · Virtici, Llc · R44 · FY2018 · AI
Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children
$989,945Will Clifton · Polyvascular Corporation · R44 · FY2022 · HL
Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis
$989,930Jenny J Yang · Inlighta Biosciences, Llc · UT2 · FY2020 · AA
Development of a TRAIL-based therapy for alcohol related chronic pancreatitis
$988,751Victor V Roschke · Theraly Fibrosis, Inc. · U44 · FY2018 · AA
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
$988,238Robert Tarran · Eldec Pharmaceuticals, Inc. · R42 · FY2022 · AI
Novel Biguanides to Treat Type 2 Diabetes
$987,938Ken W Batchelor · Novatarg, Inc. · R44 · FY2016 · DK
Humanized monoclonal antibodies to treat mucormycosis
$987,901Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2023 · AI
Optimization of novel pyranopyridine efflux pump inhibitors
$987,681Timothy J Opperman · Microbiotix, Inc · R44 · FY2019 · AI
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
$987,570Ward Peterson · Symberix, Inc. · R44 · FY2019 · CA
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
$987,515Kevin Trabbic · Bluewillow Biologics, Inc. · R44 · FY2022 · AI
Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy
$986,763Angela Hansen · Winsantor, Inc. · R44 · FY2015 · DK
Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections
$986,717Edward Gershburg · Rational Vaccines, Inc. · R44 · FY2025 · AI
Targeted delivery of Lu-177 to tumor vasculature
$985,550Joseph M Backer · Sibtech, Inc. · R44 · FY2012 · CA
Preclinical development of PPCM vaginal contraceptive to submit IND.
$985,250Mary B Weitzel · Yaso Therapeutics Inc · R44 · FY2017 · HD
Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis
$984,309Jenny J Yang · Inlighta Biosciences, Llc · UT2 · FY2021 · AA
National Islet Cell Consortium Coordinating Center
$984,161City Of Hope/Beckman Research Institute · U42 · FY2002 · RR
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
$984,129Frank W. Marcoux · Leukogene Therapeutics, Inc. · R42 · FY2018 · CA
Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures
$983,573Abhichart Krissanaprasit · Helixomer, Inc. · R44 · FY2023 · HL